Health Care [ 12/12 ] | Biotechnology [ 62/74 ]
NASDAQ | Common Stock
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally.
The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.
Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors.
The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460.
It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib.
The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers.
The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003.
Incyte Corporation
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Oct 29, 24 | 1.07 Decreased by -2.73% | 1.07 |
| Jul 30, 24 | -1.82 Decreased by -283.84% | -1.55 Decreased by -17.42% |
| Apr 30, 24 | 0.64 Increased by +72.97% | 0.84 Decreased by -23.81% |
| Feb 13, 24 | 1.06 Increased by +70.97% | 1.16 Decreased by -8.62% |
| Oct 31, 23 | 1.10 Increased by +83.33% | 1.02 Increased by +7.84% |
| Aug 1, 23 | 0.99 Decreased by -1.98% | 0.83 Increased by +19.28% |
| May 2, 23 | 0.37 Decreased by -32.73% | 0.76 Decreased by -51.32% |
| Feb 7, 23 | 0.62 Increased by +520.00% | 0.58 Increased by +6.90% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 1.14 B Increased by +23.81% | 106.46 M Decreased by -37.84% | Increased by +9.36% Decreased by -49.80% |
| Jun 30, 24 | 1.04 B Increased by +9.34% | -444.60 M Decreased by -318.43% | Decreased by -42.60% Decreased by -299.77% |
| Mar 31, 24 | 880.89 M Increased by +8.93% | 169.55 M Increased by +681.22% | Increased by +19.25% Increased by +617.17% |
| Dec 31, 23 | 1.01 B Increased by +9.35% | 201.08 M Increased by +606.51% | Increased by +19.84% Increased by +546.10% |
| Sep 30, 23 | 919.02 M Increased by +11.63% | 171.27 M Increased by +51.87% | Increased by +18.64% Increased by +36.05% |
| Jun 30, 23 | 954.61 M Increased by +4.74% | 203.55 M Increased by +26.09% | Increased by +21.32% Increased by +20.38% |
| Mar 31, 23 | 808.67 M Increased by +10.29% | 21.70 M Decreased by -42.87% | Increased by +2.68% Decreased by -48.20% |
| Dec 31, 22 | 926.70 M Increased by +7.40% | 28.46 M Decreased by -94.95% | Increased by +3.07% Decreased by -95.30% |